The Board of Queensland Bauxite (ASX:QBL) is pleased to announce a materially positive update regarding the company's research into the use of medical cannabis in autoimmune disease treatment.
Queensland Bauxite Ltd (ASX:QBL) provides the Company's Quarterly Report.
Further to the Transformation Announcement made on 20 June 2018, the Board of Queensland Bauxite Limited (ASX:QBL) has recognised that due to current market conditions, the intended capital raise at 8c is no longer an immediate practical option. As a result, the Board has decided to amend the raising price for the recompliance.
Australian Bauxite Limited (ASX:ABX) is pleased to announce that its wholly-owned subsidiary, ALCORE Limited has secured the minimum funding needed to commence Stage 1 of the ALCORE Project. Site construction works commenced on 1 July as planned at ALCORE's pre-approved Pilot Plant site in Berkeley Vale, Central Coast NSW for the production of AlF3 test samples.
Queensland Bauxite Limited (ASX:QBL) is delighted to announce that Medcan Australia, has now been issued with both an Import & Export Licence under the ODC.
Australian Bauxite Limited (ASX:ABX) is pleased to advise that Australian Bauxite Limited and Aziz Group of Bangladesh have successfully negotiated a Letter of Intent over two important opportunities for bauxite sales and future business development.
As reported in the announcement released by Queensland Bauxite Limited (ASX:QBL) on 13th July 2018, the Notice of Meeting for the recompliance transactions is still being drafted and is yet to be reviewed by the ASX. The following table is the timeline to which the Company is currently working towards for the completion of the transactions and the recompliance requirements.
